glp-1 biosimilar Biosimilars: Mass Spectrometry Challenges in Semaglutide and Exenatide Characterization Bioanalysis of GLP-1 Antagonist Drugs

Description

Summary: GLP-1 receptor agonists are not licensed for anxiety treatment and lack established evidence for direct anxiolytic effects, though some patients may experience secondary psychological improvements through metabolic health gains

By using AI to analyze more than 400,000 Reddit posts, researchers at Penns School of Engineering and Applied Science have identified patient-reported symptoms associated with GLP-1s, the popular weight-loss and diabetes drugs semaglutide and tirzepatide, that may not be fully captured in clinical trials or regulatory documents

Metabolic improvements often begin within weeks, before significant weight loss occurs

202,203,204 Moreover, Akt can activate mTORC1, further promoting cell growth and protein synthesis

Insulin and glucagon-like peptide 1 receptor agonist combination therapy in type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials